1.Comparative analysis of medicines varieties and dosage forms between UAE and China
Journal of Pharmaceutical Practice and Service 2022;40(5):454-463
Objective To understand the supply situation of the UAE’s medicinal market and provide reference for Chinese medicines which are going to import into the UAE. Methods The data related to the existing varieties and dosage forms in the UAE’s medicinal market were collected and analyzed, and compared to the medicines in China. Results To December 31st, 2021, the number of existing pharmaceutical products in the UAE was 5 395 and the number of varieties was 1 637. According to the statistical results of the New Pharmacotherapeutics (18th Edition), the number of pharmaceutical varieties in China was 1 558. The number of overlapping pharmaceutical varieties between the two countries was 604, and the differences mainly focus on medicines of alimentary tract and metabolism, anti-infectives for systemic use, medicines for the nervous system, antiparasitic products, insecticides and repellents. There were 194 pharmaceutical dosage forms in the UAE, with oral administration, injectable administration and dermal administration ranking among the top three. Conclusion There are certain commonalities and also differences in pharmaceutical varieties and dosage forms between China and the UAE, which indicated that our pharmaceutical varieties need to be investigated in detail before importing into the UAE. At the same time, China also could learn from the experience of the UAE and strengthen the research of new medicines and mechanical combinations to further enrich the domestic pharmaceutical market.
2.Acetaminophen content assay with UHPLC in the sustained-release tablet exposed to radiation
Dexun YU ; Xinhui HUANG ; Kehan ZHU ; Ting HUANG ; Tingting ZHOU ; Jianyi GAO
Journal of Pharmaceutical Practice and Service 2022;40(6):550-552
Objective To assay the contents of acetaminophen with ultra high-performance liquid chromatography (UHPLC) method in the sustained-release tablets radiated by Gamma ray. Methods Acetaminophen sustained-release tablets were radiated by 60Co. UHPLC equipped with the Shim-pack GISS-C18(2.1 mm×50 mm, 1.9 μm)was used for the assay. The mobile phase was methanol-0.05 % ammonium acetate solution (15∶85). The flow rate was 0.3 ml/min with the detection wavelength at 245 nm. Results The acetaminophen showed good linear relationship within the range of 20-100 μg/ml (r=0.999 4). The RSD values of repeatability was 0.9 %. The average recovery was 97.9 %-104.9 %. Acetaminophen content was 96.2 %, 92.2 %, 91.8 %, 83.9 % at 0, 8, 50 and 80 kGy radiation, respectively. Conclusion This method is speedy and accurate. It can be used to assay the content of acetaminophen in the sustained-release tablets after radiation. The content of acetaminophen decreased after radiation.
3.Advances in antidepressant therapy related to gut microbiota
Qiannan WANG ; Xinhui HUANG ; Minxu YANG ; Xingrui YANG ; Kehan ZHU ; Tingting ZHOU
Journal of Pharmaceutical Practice and Service 2022;40(5):422-426
Objective This paper introduces the research progress on the pathogenesis of depression related to gut microbiota and provides the resources for the subsequent development of antidepressant drugs targeting gut microbiota. Methods 33 literatures on gut microbiota and depression in recent years were reviewed. The changes of gut microbiota diversity under depression were discussed from the perspectives of phylum, family and genus. The relationship between gut microbiota and the pathogenesis of depression was expounded at the molecular level, and the existing relevant studies were summarized. The feasibility of drug development targeting gut microbiota was explored. Results There is a relationship between gut microbiota disorder and depression. Existing biological agents such as probiotics can alleviate depression by adjusting the disorder of gut microbiota. Conclusion The imbalance of gut microbiota is closely related to the occurrence of depression, and the development of drugs targeting gut microbiota may become a new way to treat depression.
4.Transapical transcatheter aortic valve replacement in bicuspid aortic valve patients: In-hospital outcomes
Xuan HUANG ; Lulu LIU ; Tingxi ZHU ; Kehan LI ; Yingqiang GUO ; Xiaoyan YANG
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2023;30(08):1128-1136
Objective To compare the in-hospital outcomes of transapical transcatheter aortic valve replacement (TA-TAVR) for bicuspid aortic valve (BAV) patients and tricuspid aortic valve (TAV) patients. Methods Patients (including BAV and TAV patients) who underwent TA-TAVR with the J-ValveTM in West China Hospital from July 2014 to July 2020 were included consecutively. The clinical outcomes of the patients were analyzed. Results A total of 354 patients were included in the study, 75 in the BAV group and 279 in the TAV group. There were 229 males and 125 females with a mean age of 72.2±6.0 years. No death occurred during the procedure, and the overall technical success rate was 97.7%. The all-cause in-hospital mortality rate was 1.4%. Twenty (26.7%) patients with BAV and 46 (16.5%) patients with TAV had mild or higher perivalvular leaks immediately after the procedure. No patients with BAV required permanent pacemaker implantation postoperatively, while 13 (4.7%) TAV patients required permanent pacemaker implantation, with an overall pacemaker implantation rate of 3.7%. One (1.3%) BAV patient and 7 (2.5%) TAV patients developed acute kidney injury postoperatively. One (1.3%) BAV patient and 1 (0.4%) TAV patient developed peri-operative myocardial infarction. The average postoperative hospital stay was 7.6±3.6 d for BAV patients and 8.6±6.1 d for TAV patients. There was no statistical difference in primary or secondary in-hospital outcomes between BAV and TAV patients (P>0.05). Conclusion Compared to TAV patients, BAV patients have similar in-hospital outcomes, with a low incidence of adverse clinical outcomes, which provides preliminary evidence for its implementation in Chinese patients with a high proportion of BAV.